Intensity Therapeutics Announces Results of 2026 Annual Meeting of Stockholders

On June 16, 2026, Intensity Therapeutics held its Annual Meeting of Stockholders. Shareholders voted on several key proposals, including the election of two Class III directors, Dr. Emer Leahy and Lewis H. Bender, to serve until the 2029 annual meeting. Both nominees were successfully elected. Additionally, stockholders ratified the selection of EisnerAmper LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The meeting also resulted in the approval of amendments to the company's equity incentive structures. Stockholders approved an amendment to the 2021 Stock Incentive Plan to increase the number of shares available for sale by 150,000. Furthermore, an amendment to the 2024 Employee Stock Purchase Plan (ESPP) was approved, increasing the shares available by 25,000. Finally, a proposal allowing for the postponement or adjournment of the meeting to solicit additional proxies was approved, though it was not utilized as the other measures passed. A quorum was present with approximately 40.74% of outstanding shares represented.